---
title: "波士顿科学涨超 4.4%，Q3 业绩超预期 + 上调全年调整后盈利指引"
description: "波士顿科学股价上涨超过 4.4%，报 104.36 美元。第三季度销售额同比增长 20% 至 50.7 亿美元，超出分析师预期。心血管部门销售额增长 22% 至 33.4 亿美元，调整后每股收益为 75 美分，高于预期。公司上调全年调整后每股收益指引至 3.02 至 3.04 美元，超过分析师预期的 2.98 美元。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262272160.md"
published_at: "2025-10-22T14:50:21.000Z"
---

# 波士顿科学涨超 4.4%，Q3 业绩超预期 + 上调全年调整后盈利指引

> 波士顿科学股价上涨超过 4.4%，报 104.36 美元。第三季度销售额同比增长 20% 至 50.7 亿美元，超出分析师预期。心血管部门销售额增长 22% 至 33.4 亿美元，调整后每股收益为 75 美分，高于预期。公司上调全年调整后每股收益指引至 3.02 至 3.04 美元，超过分析师预期的 2.98 美元。

医疗器械公司波士顿科学涨超 4.4%，报 104.36 美元。消息面上，波士顿科学第三季度销售额同比增长 20% 至 50.7 亿美元，超出华尔街分析师预期的 49.7 亿美元。其中，心血管部门的销售额同比增长 22% 至 33.4 亿美元，高于预期的 32.7 亿美元。期内调整后每股收益为 75 美分，高于预期的 71 美分。公司上调全年调整后每股收益指引至 3.02 至 3.04 美元，超过分析师预期的 2.98 美元。

### Related Stocks

- [BSX.US - 波士顿科学](https://longbridge.com/zh-CN/quote/BSX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer | Boston Scientific (BSX) is conducting the TheraSphere Japan Pre-Market Study to evaluate a liver cancer treatment for pa | [Link](https://longbridge.com/zh-CN/news/276465329.md) |
| Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX | Assetmark Inc. has reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 41.6%, selling 82,501 shares in the  | [Link](https://longbridge.com/zh-CN/news/276044910.md) |
| If You Invested $100 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today | Boston Scientific (NYSE:BSX) has delivered an average annual return of 18.55% over the past 15 years, outperforming the  | [Link](https://longbridge.com/zh-CN/news/271667047.md) |
| Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst | TD Cowen analyst Josh Jennings maintains a Buy rating on Boston Scientific (BSX), citing unjustified recent share weakne | [Link](https://longbridge.com/zh-CN/news/272882910.md) |
| Boston Scientific Corporation $BSX Shares Purchased by Gladstone Institutional Advisory LLC | Gladstone Institutional Advisory LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 39.5% in Q3, own | [Link](https://longbridge.com/zh-CN/news/271652191.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。